ClinicalTrials.gg
TerminatedNCT02108951ENESTswiftUpdated Oct 27, 2017Results posted

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

A Phase 3 interventional study of Nilotinib in Philidelphia Positive Chronic Myeloid Leukaemia, sponsored by Novartis Pharmaceuticals. Terminated at 14 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-27.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. The study's title name Leukemia, Myelogenous, Chronic, BCR-ABL Positive, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated because of slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
47th of 66
20 · median 55
Started
2014
with 4 others
Phase 3
15 of 66
none open now
Registered
49th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 47th largest by enrollment, is one of 5 that started in 2014, is one of 15 in phase 3, and was the 49th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this Australian study was to assess the efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia chronic phase who were intolerant but responsive to 1st line treatment with imatinib or dasatinib. Eligible patients have been previously treated with imatinib or dasatinib for at least 3 months and are experiencing non-hematologic toxicity whilst having documented responses that meet PBS authority for 1st line treatment of CML without current MR4.5.

Read the detailed description

The study was planned to enroll 130 patients to achieve the sample size requirement for a meaning full conclusion. Study got terminated with 20 patients because of slow recruitment. Therefore, due to small sample size, the results cannot be considered clinical significant.

03

Conditions studied

  • Philidelphia Positive Chronic Myeloid Leukaemia

Browse trials for

Keywords

  • CML
  • Ph-CML
  • leukaemia
  • leukemia
  • chronic myeloid leukemia
  • chronic myeloid leukaemia
  • TKI intolerance
  • tyrosine kinase inhibitor
  • tyrosine kinase inhibitor intolerance
04

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 20 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Written prior to screening procedures
  2. Eastern Cooperative Oncology Grou () Performance Status of 0, 1, or 2.
  3. Patient with diagnosis of Ph+ CML-CP associated with BCR-ABL quantifiable by RQ-PCR (IS).
  4. Patient has received a minimum of 3 months of imatinib or dasatinib treatment (any dose) since initial diagnosis with a documented response.
  5. Patient is eligible for Pharmaceutical Benefits Scheme (PBS) reimbursed TKI treatment.
  6. Patient has experienced non-hematological Adverse Events (AE(s)) of any grade, which persisted for at least 1 month despite supportive care or recurred at any grade at least once. Patients who, at the Investigator's discretion, require immediate discontinuation due to the severity of the adverse event are also eligible.
  7. No other current or planned anti-leukemia therapies.
  8. Adequate organ function.
  9. Potassium, Magnesium and Total Calcium above Lower limit of normal.
  10. of more than 12 months in the absence of any intervention

Key Exclusion Criteria:

  1. Prior treatment with nilotinib.
  2. Prior Accelerated Phase (AP), Blast Crisis (BC) or -transplant (unless the patient received an autologous transplant and was in Chrionic Phase (CP) prior to transplant and never in AP or BC).
  3. Patient has documented Molecular Response (MR) 4.5 at the time of study entry
  4. Patients with atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.
  5. Known impaired cardiac function.
  6. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
  7. Pregnant or breast feeding (lactating) women.
  8. Women of unwilling or unable to use highly effective .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.

    Drug: Nilotinib

Interventions

  • Nilotinib 150mg hard gelatin capsules taken orally

    Also known as: AMN107

07

What researchers measure

Primary outcomes

  1. Deep Molecular Response (MR4.5) Rate: Percentage of Patients Who Have Achieved a 4.5-log Reduction in BCR-ABL Level Within 24 Month

    Deep Molecular Response (MR4.5) rate is defined as the percentage of patients who have achieved a 4.5 -log reduction in Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels. BCR-ABL levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

    Time frame: Baseline, 96 weeks (24 months)

  2. Molecular Response (MR4.0) Rate: Percentage of Patients Who Have Achieved a 4.0-log Reduction in BCR-ABL Level Within 12 Months and 24 Months

    Molecular Response (MR4.0) rate is defined as the percentage of patients who have achieved a 4-log reduction in BCR-ABL levels at 12 months and 24 months following the commencement of nilotinib therapy. Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.0 corresponds to a BCR-ABL ratio 0.01% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patients were classified as achieving a 1 log reduction in BCR-ABL.

    Time frame: Baseline, 48 weeks (12 months), 96 weeks (24 months)

  3. Major Molecular Response (MMR) Rate: Percentage of Patients Who Have Achieved a 3 Log Reduction in BCR-ABL Levels Within 12 Months and 24 Months

    Major Molecular Response (MMR) rate is defined as the percentage of patients who have achieved a 3 log reduction in BCR-ABL levels at 12 months and at 24 months following the commencement of nilotinib therapy. Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood at the 12 and 24 months following the commencement of nilotinib therapy. MMR corresponds to a BCR-ABL ratio 0.1% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 \* the baseline Value, the patient will be classified as achieving a 1 log drop.

    Time frame: Baseline, 48 weeks (12 months), 96 weeks (24 months)

  4. Duration of Prior TKI Therapy for Patients Based on MR4.5 Achievement Status Within 24 Months

    Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. Deep molecular response (MR4.5) rate was defined as the percentage of patients who have achieved a 4.5-log reduction (MR4.5) in BCR-ABL levels during the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% IS using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

    Time frame: Baseline, 96 weeks (24 months)

  5. Number of Patients With MR4.5 Response by Baseline BCR-ABL Response Level Within 24 Months

    Deep Molecular Response (MR4.5) rate is defined as the percentage of patients who have achieved a 4.5 -log reduction in Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels. BCR-ABL levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

    Time frame: Baseline, 96 weeks (24 months)

Secondary outcomes

  1. Kinetics of Molecular Response: Percentage of Patients With no Response Based on BCR-ABL Over Time After the Switch to Nilotinib

    No response corresponds to a BCR-ABL ratio \< 0.1% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

    Time frame: Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96

  2. Kinetics of Molecular Response: Percentage of Patients With MMR Based on BCR-ABL Over Time After the Switch to Nilotinib

    MMR corresponds to a BCR-ABL ratio 0.1% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

    Time frame: Baseline, week 4, 8, 12, 24, 36, 48, 60, 72 and 96

  3. Kinetics of Molecular Response: Percentage of Patients With MR4.0 Based on BCR-ABL Over Time After the Switch to Nilotinib

    MR4.0 corresponds to a BCR-ABL ratio 0.01% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

    Time frame: Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96

  4. Kinetics of Molecular Response: Percentage of Patients With MR4.5 Based on BCR-ABL Over Time After the Switch to Nilotinib

    MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

    Time frame: Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96

  5. Kaplan-Meier Estimates of Time to Deep Molecular Response (MR4.5)

    Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels is measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% IS using RQ-PCR. The derivation of time to molecular response for patients in the study was measured from the date of first nilotinib use, defined as follows: Days to MR4.5 = date of assessment where BCR-ABL ratio is 0.0032% IS - date of baseline + 1.

    Time frame: 96 weeks (24 months)

  6. Time to Progression-free Survival (PFS)

    PFS was defined as the time from the date of baseline visit to the date of earliest progression-defining event: namely progression (or withdrawal due to progression to blast crisis (BC) or accelerated phase (AP) disease), or death from any cause. Patients who did not progress were censored at earliest of the following: * the date of the 24-month visit; * the date of loss to follow-up; * the date of discontinuation of study treatment for any reason other than progression to BC, or AP disease, or death

    Time frame: 96 weeks (24 months)

  7. Time to Event Free Survival (EFS)

    EFS was defined as the time from date of baseline visit to the first occurrence of any of the following: Disease progression, treatment failure or death from any cause, whichever was earlier. Patients who did not have an event of interest were censored at earliest of the following: * the date of the 24-month visit; * the date of loss to follow-up; * the date of withdrawal from the study for any reason other than lack of efficacy/progressive disease, tolerance to reduced dose or death

    Time frame: 96 weeks (24 months)

  8. Number of Patients With Events Reported at Baseline That Have Shown an Improvement in Non-hematological AE Severity Compared to Week 12 Visit

    The total number of patients that have showed improvement with respect to CTCAE grades at the time of the 12-week visit are reported. Improved is defined as prior to, or at the time of the 12-week visit, the AE has completely resolved.

    Time frame: Baseline, week 12 (month 3)

  9. Mean M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML)

    Quality of life was assessed using the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) self-administered questionnaire for adult CML patients. The questionnaire consisted of 13 core questions in part I measuring the severity of symptoms, 6 questions in part 2 assessing the interference of symptoms on daily living. The CML component of the MDASI provided an additional 7 CML-specific symptom items: diarrhea, swelling, rash/skin change, muscle soreness/cramping, bruising/bleeding easily, malaise, and headache. In part I (13 questions) and the CML component (7 questions) each question was scored from 0 to 10 where 0 indicates a symptom is not present and 10 indicate the symptom is "as bad as you can imagine". For part 1 the total score can therefore range from 0 to 130 and for CML 0 to 70. Part 2 is also recorded on a 0 to 10 scale, but 0 now indicates that the symptom "did not interfere" and 10 "interfered completely". The total score can range from 0 to 60.

    Time frame: Baseline, week 12, 24, 48, 96

08

Results

Posted Oct 27, 2017
Limitations and caveats
The study was planned to enroll 130 patients. Study got terminated with 20 patients because of slow recruitment. Therefore, due to small sample size, the results cannot be considered clinical significant.

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started20
Completed4
Not completed16
Withdrew: Lost to follow-up1
Withdrew: Patient's/guardian's decision1
Withdrew: Study terminated by sponsor14

Outcome measures

PrimaryDeep Molecular Response (MR4.5) Rate: Percentage of Patients Who Have Achieved a 4.5-log Reduction in BCR-ABL Level Within 24 Month

Deep Molecular Response (MR4.5) rate is defined as the percentage of patients who have achieved a 4.5 -log reduction in Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels. BCR-ABL levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

Time frame:
Baseline, 96 weeks (24 months)
Reported as:
Number · Percentage of participants
Deep Molecular Response (MR4.5) Rate: Percentage of Patients Who Have Achieved a 4.5-log Reduction in BCR-ABL Level Within 24 Month
Percentage of participantsNilotinib
Deep Molecular Response (MR4.5) Rate: Percentage of Patients Who Have Achieved a 4.5-log Reduction in BCR-ABL Level Within 24 Month50 (27.2 to 72.8)
PrimaryMolecular Response (MR4.0) Rate: Percentage of Patients Who Have Achieved a 4.0-log Reduction in BCR-ABL Level Within 12 Months and 24 Months

Molecular Response (MR4.0) rate is defined as the percentage of patients who have achieved a 4-log reduction in BCR-ABL levels at 12 months and 24 months following the commencement of nilotinib therapy. Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.0 corresponds to a BCR-ABL ratio 0.01% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patients were classified as achieving a 1 log reduction in BCR-ABL.

Time frame:
Baseline, 48 weeks (12 months), 96 weeks (24 months)
Reported as:
Number · Percentage of participants
Molecular Response (MR4.0) Rate: Percentage of Patients Who Have Achieved a 4.0-log Reduction in BCR-ABL Level Within 12 Months and 24 Months
Percentage of participantsNilotinib
Within 12 months65 (38.3 to 85.8)
Within 24 months71 (44.0 to 89.7)
PrimaryMajor Molecular Response (MMR) Rate: Percentage of Patients Who Have Achieved a 3 Log Reduction in BCR-ABL Levels Within 12 Months and 24 Months

Major Molecular Response (MMR) rate is defined as the percentage of patients who have achieved a 3 log reduction in BCR-ABL levels at 12 months and at 24 months following the commencement of nilotinib therapy. Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood at the 12 and 24 months following the commencement of nilotinib therapy. MMR corresponds to a BCR-ABL ratio 0.1% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 \* the baseline Value, the patient will be classified as achieving a 1 log drop.

Time frame:
Baseline, 48 weeks (12 months), 96 weeks (24 months)
Reported as:
Number · Percentage of participants
Major Molecular Response (MMR) Rate: Percentage of Patients Who Have Achieved a 3 Log Reduction in BCR-ABL Levels Within 12 Months and 24 Months
Percentage of participantsNilotinib
Within 12 months75 (34.9 to 96.8)
Within 24 months75 (34.9 to 96.8)
PrimaryDuration of Prior TKI Therapy for Patients Based on MR4.5 Achievement Status Within 24 Months

Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. Deep molecular response (MR4.5) rate was defined as the percentage of patients who have achieved a 4.5-log reduction (MR4.5) in BCR-ABL levels during the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% IS using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

Time frame:
Baseline, 96 weeks (24 months)
Reported as:
Mean · months
Duration of Prior TKI Therapy for Patients Based on MR4.5 Achievement Status Within 24 Months
monthsNilotinib
Achieved MR4.556.1 ± 42.06
Did not achieve MR4.545.9 ± 47.81
PrimaryNumber of Patients With MR4.5 Response by Baseline BCR-ABL Response Level Within 24 Months

Deep Molecular Response (MR4.5) rate is defined as the percentage of patients who have achieved a 4.5 -log reduction in Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels. BCR-ABL levels are measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using RQ-PCR. If a post-baseline value for BCR-ABL is \< 0.1 X the baseline value, the patient were classified as achieving a 1 log reduction in BCR-ABL.

Time frame:
Baseline, 96 weeks (24 months)
Reported as:
Count of participants · Participants
Number of Patients With MR4.5 Response by Baseline BCR-ABL Response Level Within 24 Months
ParticipantsNilotinib
MR4.5 achieved (n=10): No response at baseline3
MR4.5 achieved : MMR at baseline4
MR4.5 achieved : MR4.0 at baseline1
MR4.5 achieved: MR4.5 at baseline2
MR4.5 not achieved: No response at baseline5
MR4.5 not achieved: MMR at baseline5
MR4.5 not achieved: MR4.0 at baseline0
MR4.5 not achieved: MR4.5 at baseline0
SecondaryKinetics of Molecular Response: Percentage of Patients With no Response Based on BCR-ABL Over Time After the Switch to Nilotinib

No response corresponds to a BCR-ABL ratio \< 0.1% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

Time frame:
Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
Reported as:
Number · percentage of patients
Kinetics of Molecular Response: Percentage of Patients With no Response Based on BCR-ABL Over Time After the Switch to Nilotinib
percentage of patientsNilotinib
Baseline : No Response40.0
Week 4: No response33.3
Week 8: No response26.3
Week 12: No response15.0
Week 24: No response18.8
Week 36: No response6.7
Week 48: No response7.1
Week 60: No response0.0
Week 72: No response0.0
Week 84: No response0.0
Week 96/End of study: No response5.6
SecondaryKinetics of Molecular Response: Percentage of Patients With MMR Based on BCR-ABL Over Time After the Switch to Nilotinib

MMR corresponds to a BCR-ABL ratio 0.1% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

Time frame:
Baseline, week 4, 8, 12, 24, 36, 48, 60, 72 and 96
Reported as:
Number · percentage of patients
Kinetics of Molecular Response: Percentage of Patients With MMR Based on BCR-ABL Over Time After the Switch to Nilotinib
percentage of patientsNilotinib
Baseline : MMR45.0
Week 4: MMR55.6
Week 8: MMR36.8
Week 12: MMR40.0
Week 24: MMR31.3
Week 36: MMR26.7
Week 48: MMR28.6
Week 60: MMR12.5
Week 72: MMR0.0
Week 84: MMR0.0
Week 96/End of study: MMR33.3
SecondaryKinetics of Molecular Response: Percentage of Patients With MR4.0 Based on BCR-ABL Over Time After the Switch to Nilotinib

MR4.0 corresponds to a BCR-ABL ratio 0.01% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

Time frame:
Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
Reported as:
Number · percentage of patients
Kinetics of Molecular Response: Percentage of Patients With MR4.0 Based on BCR-ABL Over Time After the Switch to Nilotinib
percentage of patientsNilotinib
Baseline : MR4.05.0
Week 4: MR4.05.6
Week 8: MR4.015.8
Week 12: MR4.010.0
Week 24: MR4.018.8
Week 36: MR4.020.0
Week 48: MR4.014.3
Week 60: MR4.012.5
Week 72: MR4.060.0
Week 84: MR4.033.3
Week 96/End of study: MR4.016.7
SecondaryKinetics of Molecular Response: Percentage of Patients With MR4.5 Based on BCR-ABL Over Time After the Switch to Nilotinib

MR4.5 corresponds to a BCR-ABL ratio 0.0032% international scale (IS) using Real-time quantitative polymerase chain reaction (RQ-PCR).

Time frame:
Baseline, week 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
Reported as:
Number · percentage of patients
Kinetics of Molecular Response: Percentage of Patients With MR4.5 Based on BCR-ABL Over Time After the Switch to Nilotinib
percentage of patientsNilotinib
Baseline : MR4.510.0
Week 4: MR4.55.6
Week 8: MR4.521.1
Week 12: MR4.535.0
Week 24: MR4.531.3
Week 36: MR4.546.7
Week 48: MR4.550.0
Week 60: MR4.575.0
Week 72: MR4.540.0
Week 84: MR4.566.7
Week 96/End of study: MR4.544.4
SecondaryKaplan-Meier Estimates of Time to Deep Molecular Response (MR4.5)

Breakpoint cluster region - Abelson murine leukemia (BCR-ABL) levels is measured in patients by real-time quantitative polymerase chain reaction (RQ-PCR) testing of peripheral blood by the 24 months following the commencement of nilotinib therapy. MR4.5 corresponds to a BCR-ABL ratio 0.0032% IS using RQ-PCR. The derivation of time to molecular response for patients in the study was measured from the date of first nilotinib use, defined as follows: Days to MR4.5 = date of assessment where BCR-ABL ratio is 0.0032% IS - date of baseline + 1.

Time frame:
96 weeks (24 months)
Reported as:
Median · days
Kaplan-Meier Estimates of Time to Deep Molecular Response (MR4.5)
daysNilotinib
Kaplan-Meier Estimates of Time to Deep Molecular Response (MR4.5)343 (64 to NA)
SecondaryTime to Progression-free Survival (PFS)

PFS was defined as the time from the date of baseline visit to the date of earliest progression-defining event: namely progression (or withdrawal due to progression to blast crisis (BC) or accelerated phase (AP) disease), or death from any cause. Patients who did not progress were censored at earliest of the following: * the date of the 24-month visit; * the date of loss to follow-up; * the date of discontinuation of study treatment for any reason other than progression to BC, or AP disease, or death

Time frame:
96 weeks (24 months)

No measurements were reported for this outcome.

SecondaryTime to Event Free Survival (EFS)

EFS was defined as the time from date of baseline visit to the first occurrence of any of the following: Disease progression, treatment failure or death from any cause, whichever was earlier. Patients who did not have an event of interest were censored at earliest of the following: * the date of the 24-month visit; * the date of loss to follow-up; * the date of withdrawal from the study for any reason other than lack of efficacy/progressive disease, tolerance to reduced dose or death

Time frame:
96 weeks (24 months)

No measurements were reported for this outcome.

SecondaryNumber of Patients With Events Reported at Baseline That Have Shown an Improvement in Non-hematological AE Severity Compared to Week 12 Visit

The total number of patients that have showed improvement with respect to CTCAE grades at the time of the 12-week visit are reported. Improved is defined as prior to, or at the time of the 12-week visit, the AE has completely resolved.

Time frame:
Baseline, week 12 (month 3)
Reported as:
Count of participants · Participants
Number of Patients With Events Reported at Baseline That Have Shown an Improvement in Non-hematological AE Severity Compared to Week 12 Visit
ParticipantsNilotinib
Improved : Yes11
Improved: No9
SecondaryMean M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML)

Quality of life was assessed using the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) self-administered questionnaire for adult CML patients. The questionnaire consisted of 13 core questions in part I measuring the severity of symptoms, 6 questions in part 2 assessing the interference of symptoms on daily living. The CML component of the MDASI provided an additional 7 CML-specific symptom items: diarrhea, swelling, rash/skin change, muscle soreness/cramping, bruising/bleeding easily, malaise, and headache. In part I (13 questions) and the CML component (7 questions) each question was scored from 0 to 10 where 0 indicates a symptom is not present and 10 indicate the symptom is "as bad as you can imagine". For part 1 the total score can therefore range from 0 to 130 and for CML 0 to 70. Part 2 is also recorded on a 0 to 10 scale, but 0 now indicates that the symptom "did not interfere" and 10 "interfered completely". The total score can range from 0 to 60.

Time frame:
Baseline, week 12, 24, 48, 96
Reported as:
Mean · units on a scale
Mean M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML)
units on a scaleNilotinib
Baseline: MDASI part 126.6 ± 23.88
Week 12: MDASI part 122.7 ± 20.31
Week 24: MDASI part 120.7 ± 18.08
Week 48: MDASI part 120.4 ± 16.57
Week 96: MDASI part 117.5 ± 20.44
Baseline: MDASI part 212.4 ± 14.17
Week 12: MDASI part 27.8 ± 11.92
Week 24: MDASI part 28.2 ± 12.20
Week 48: MDASI part 27.6 ± 10.53
Week 96: MDASI part 29.9 ± 15.59
Baseline: CMLcomponent40.9 ± 35.02
Week 12: CMLcomponent31.5 ± 30.10
Week 24: CMLcomponent30.8 ± 28.62
Week 48: CMLcomponent28.2 ± 24.43
Week 96 CMLcomponent25.4 ± 31.06

Adverse events

Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—1/20 (5%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventNilotinib
PneumoniaInfections and infestations1/20
Most frequent other events
Showing 10 of 24
Most frequent other events
EventNilotinib
FatigueGeneral disorders11/20
ConstipationGastrointestinal disorders4/20
Gastrooesophageal reflux diseaseGastrointestinal disorders4/20
Upper respiratory tract infectionInfections and infestations4/20
Gamma-glutamyltransferase increasedInvestigations4/20
Bone painMusculoskeletal and connective tissue disorders4/20
Muscle spasmsMusculoskeletal and connective tissue disorders4/20
Urinary tract infectionInfections and infestations3/20
Back painMusculoskeletal and connective tissue disorders3/20
RashSkin and subcutaneous tissue disorders3/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nilotinib
Mean53.9 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female14
Male6
09

Study locations

14 sites
  • Novartis Investigative Site
    Canberra, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Kingswood, New South Wales 2747, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    St. Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Douglas, Queensland 4810, Australia
  • Novartis Investigative Site
    Nambour, Queensland 4560, Australia
  • Novartis Investigative Site
    South Brisbane, Queensland 4101, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Fitzroy, Victoria 3065, Australia
  • Novartis Investigative Site
    Geelong, Victoria 3220, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Aug 2016, 25 months.

Results were first posted in Oct 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2014
First posted
Apr 9, 2014
StartActual
Jul 7, 2014
Primary completionActual
Aug 10, 2016
CompletionActual
Aug 10, 2016
Results first posted
Oct 27, 2017
Last update
Oct 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02108951
Responsible party
Sponsor
First posted
Apr 9, 2014
Start date
Jul 7, 2014
Primary completion
Aug 10, 2016
Completion
Aug 10, 2016
Results posted
Oct 27, 2017
Last update
Oct 27, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion